| Name | Title | Contact Details |
|---|
ZBx Corporation is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Analytical Services is a Williston, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.
Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.
Roe Dental Lab is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.